Company news

Gossamer Bio, Inc. (NASDAQ:GOSS) news

Gossamer Bio, Inc. news releases on 6ix. Latest, Sep 23, 2026: Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment…

Gossamer Bio, Inc. (NASDAQ:GOSS) news

Press releases & updates

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Gossamer Bio to Present at Cantor Global Healthcare Conference

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS

Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Gossamer Bio to Present at Upcoming Investor Conferences

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Gossamer Bio Announces $212 Million Private Placement Financing